|
- Dupixent Gets FDA Approval for COPD - WebMD
First approved in 2017, Dupixent is available as an injection in a prefilled pen It will be used as an add-on maintenance treatment for adults whose COPD is not well controlled with inhalers
- A New COPD Treatment is FDA Approved
On June 26, 2024, Verona Pharmaceuticals announced that its new medication, Ensifentrine (Ohtuvayre), was approved by the U S Food and Drug Administration (FDA) for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD)
- Dupixent approved in the US as the first-ever biologic medicine for . . .
This latest approval represents an important next chapter for Dupixent, giving those with COPD a novel option that has demonstrated the unprecedented ability to help patients experience fewer exacerbations, while also helping them breathe better and improve quality of life in phase 3 studies ”
- FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help
- Dupixent as New Treatment for COPD - HealthCentral
Last year, Sanofi and Regeneron announced the results of their phase 3 clinical trial investigating Dupixent as a potential treatment for COPD The study showed that the drug reduced COPD
- DUPIXENT® (dupilumab) for Adults with COPD
Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic treatment for adults with inadequately controlled COPD (chronic obstructive pulmonary disease) and a high number of blood eosinophils
- FDA Approves Dupixent as First Biologic for COPD Maintenance
On September 27, the US Food and Drug Administration (FDA) approved dupilumab (Dupixent, Sanofi Regeneron) as an add-on maintenance treatment for adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) Dupilumab is the first biologic medicine approved in the US for COPD
- FDA Approves Dupilumab as Add-On Maintenance Therapy For Adults With COPD
The FDA has approved dupilumab (Dupixent; Regeneron, Sanofi) as an add-on maintenance therapy for adult patients who have inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype
|
|
|